Integra LifeSciences Holdings

Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company's neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care, such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment, and the precision tools and instruments business, which sells instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices. The Tissue Technologies segment includes offerings such as skin and wound repair, bone and joint fixation implants in the upper and lower extremities, bone grafts, and nerve and tendon repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Integra LifeSciences posts solid Q4 results, eyes growth opportunities

Integra LifeSciences delivered strong financial performance in Q4 2022 and full-year 2022, showcasing operational resilience and efficiency amidst supply chain challenges and inflationary pressures.
The company's strategic focus on innovation, international growth, and operational excellence positions it well for sustainable growth in 2023, supported by new product launches and market expansion initiatives.
While facing challenges from supply chain disruptions and inflation, Integra's proactive approach to margin expansion, revenue growth, and strategic investments underscores its commitment to long-term value creation.
With a clear roadmap for 2023, including revenue growth targets, margin improvement strategies, and market expansion plans, Integra is poised to navigate challenges and capitalize on opportunities for continued success.

Integra LifeSciences exceeds Q1 expectations, eyes growth amid challenges

Integra LifeSciences demonstrated resilience and growth potential in Q1 2023, with strong segment performances and strategic initiatives.
While facing challenges like supply constraints and margin pressures, the company remains focused on operational efficiency and growth opportunities.
Reaffirmation of guidance, executive appointments, and proactive strategies position Integra well for future growth and market expansion.
Investors can expect improved performance in the second half, driven by new products, supply chain recovery, and strategic investments.

Integra LifeSciences reports Q2 challenges but shows resilience and growth

Integra LifeSciences navigated challenges from a product recall in Q2, showing resilience with solid profitability and growth in unaffected segments.
The company's strategic focus on returning critical technologies to the market, along with new leadership and financial initiatives, positions it for future success.
Despite challenges, Integra LifeSciences remains confident in regaining market share, sustaining growth momentum, and capitalizing on strategic opportunities.
Operational strengths, market performance, and proactive measures to address challenges underscore the company's resilience and growth potential.

Integra LifeSciences navigates Boston impact, eyes growth opportunities post-remediation

Integra LifeSciences faced challenges from the Boston facility recall but showed resilience with strong performance in key segments. The company is focused on growth opportunities post-Boston remediation and maintains a solid financial position. Analysts are optimistic about the company's ability to recover and grow post-recall.

Integra LifeSciences navigates challenges, eyes global growth opportunities

Integra LifeSciences faced challenges from the Boston recall impacting financials but showcased strengths in strategic product relaunches and divisional growth.
The company's performance metrics for 2023 were mixed, with declines in margins but strong cash flow generation. Opportunities lie in global growth catalysts like CereLink.
Looking ahead, Integra aims for revenue recovery post-Q1 headwinds, emphasizing international expansion and product recovery post-recall.

Integra LifeSciences reports strong Q1 results amidst operational challenges

Integra LifeSciences delivered solid Q1 results driven by revenue growth and successful acquisitions.
While facing challenges with the Boston plant audit and supply constraints, the company is focused on key priorities and opportunities for growth.
Maintaining financial stability with a clear plan to address leverage and uncertainties around product reintroduction.
Investors are closely monitoring the company's progress on key initiatives and leadership transition.

Integra LifeSciences excels in Q2 amidst compliance challenges and growth opportunities

Integra LifeSciences delivered a strong Q2 performance, focusing on operational improvements and compliance enhancements to drive long-term growth and sustainability.
While facing challenges such as revenue impacts from compliance investments and margin pressures, the company remains resilient with a strategic focus on market positioning and efficiency.
With updated guidance, successful acquisition integration, and a CEO search underway, Integra is poised to navigate challenges and capitalize on opportunities for future success.

Integra LifeSciences appoints new CEO amidst revenue challenges in Q3

Integra LifeSciences faced revenue challenges in Q3 2024 due to supply issues and compliance plan implementation. The company announced Mojdeh Poul as the new CEO to drive operational excellence and growth. Despite challenges, revenue diversification and financial stability were maintained, with a focus on future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. It operates under the Codman Specialty Surgical (CSS) and Tissue Technologies (TT) segments. The CSS segment includes technologies and instrumentation used for neurosurgery, neurocritical care, and otolaryngology. The TT segment focuses on complex wound surgery, surgical reconstruction, and peripheral nerve repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.

PRINCETON, N.J., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release third quarter 2021 financial results on Tuesday, November 2, 2021, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET.

Integra LifeSciences to Host Third Quarter 2021 Financial Results Conference Call on November 2, 2021

Integra (IART) reported earnings 30 days ago. What's next for the stock?

Integra (IART) Up 1.5% Since Last Earnings Report: Can It Continue?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Integra LifeSciences (IART) is a Top-Ranked Momentum Stock: Should You Buy?

Integra (IART) reports better-than-expected revenues with strong segmental performance driving the top line in second-quarter 2021.

Integra (IART) Q2 Earnings Top Estimates, 2021 Guidance Up

Integra LifeSciences Holdings Corporation (IART) CEO Peter Arduini on Q2 2021 Results - Earnings Call Transcript

Piper Sandler has raised the price target on Integra LifeSciences Holding Corporation (NASDAQ:IART) to $72 from $70 and reiterated a Neutral rating following the Q2 beat.  The company posted Q2 EPS of $0.79 and sales of $389.9 million, beating the consensus estimate of $0.66 and $376.0 million, respectively.

Integra's Update On FY21 Acell Revenues To Weigh On Stock, Piper Sandler Says

Shares of Integra Lifesciences (NASDAQ:IART) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share increased 139.39% over the past year to $0.79, which beat the estimate of $0.66.

Recap: Integra Lifesciences Q2 Earnings

Raises Full-Year 2021 Guidance Raises Full-Year 2021 Guidance

Integra LifeSciences Reports Second Quarter 2021 Financial Results

Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Integra LifeSciences (IART) Earnings Expected to Grow: Should You Buy?

Integra's (IART) PriMatrix study data validates that one application of PriMatrix is needed to address hard-to-heal diabetic foot ulcers.

Integra (IART) Releases Favorable PriMatrix Clinical Outcome

Data Shows a Single Application of PriMatrix Closed More Wounds Than Standard of Care Alone Data Shows a Single Application of PriMatrix Closed More Wounds Than Standard of Care Alone

Integra LifeSciences Announces Positive Clinical Outcomes for PriMatrix® Dermal Repair Scaffold for the Management of Diabetic Foot Ulcers

Integra's (IART) SurgiMend Collagen Matrix is recognized as a product that can potentially bring improvement to the health care industry.

Integra's (IART) SurgiMend Gets Innovative Technology Contract

Contract awarded for products that bring improvement to healthcare industry Contract awarded for products that bring improvement to healthcare industry

Integra LifeSciences Receives Innovative Technology Contract from Vizient for SurgiMend® Collagen Matrix for Soft Tissue Reconstruction

PRINCETON, N.J., July 08, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release second quarter 2021 financial results on Wednesday, July 28, 2021 prior to market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET.

Integra LifeSciences to Host Second Quarter 2021 Financial Results Conference Call on July 28, 2021

Peter Arduini to serve as President and CEO through the end of 2021 Candidate search launched to identify successor Peter Arduini to serve as President and CEO through the end of 2021 Candidate search launched to identify successor

Integra LifeSciences Announces CEO Succession Plan

Integra's (IART) CSS segment too reflects a gradual recovery in procedure-based market as well as an improvement in hospital capital spending during the first quarter.

Integra (IART) Tissue Technologies Rebounds Amid Supply Woe

Integra (IART) Down 8.1% Since Last Earnings Report: Can It Rebound?

PRINCETON, N.J., May 20, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will host an Investor Day meeting from 8:30 a.m. to approximately 12:30 p.m. ET, today May 20, 2021.

Integra LifeSciences Hosts Virtual Investor Day

PRINCETON, N.J., May 07, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will host an Investor Day meeting from 8:30 a.m. to approximately 12:30 p.m., U.S. eastern time on May 20, 2021.

Integra LifeSciences to Host Virtual Investor Day on May 20, 2021

Integra's (IART) first-quarter revenues improved year over year on organic growth across Codman Specialty Surgical and Tissue Technologies segments.

Integra (IART) Q1 Earnings Beat Estimates, Gross Margin Down

Integra (IART) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Integra (IART) Hits Fresh High: Is There Still Room to Run?

Integra LifeSciences Holdings Corporation (IART) CEO Peter Arduini on Q1 2021 Results - Earnings Call Transcript

Integra (IART) delivered earnings and revenue surprises of 23.21% and 2.92%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Integra LifeSciences (IART) Q1 Earnings and Revenues Top Estimates

Shares of Integra Lifesciences (NASDAQ:IART) rose 1.5% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 43.75% over the past year to $0.69, which beat the estimate of $0.57.

Integra Lifesciences: Q1 Earnings Insights

PRINCETON, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2021.

News for Integra LifeSciences Holdings Stock (IART)